PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 28, 2026Nature Communications0 citationsOpen Access

Targeting Arginine Metabolism to Combat Bone Metastasis in ARID1A-Deficient TNBC

Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShuangyue PanJWJinyan WangBWBoya Wang

Discussion

Loading...

Member takes

Overview

Randomized trial reveals targeting arginine metabolism reduces bone metastasis in ARID1A-deficient triple negative breast cancer, suggesting new treatment approaches.

Key Points

  • The aim is to understand the impact of ARID1A deficiency on bone metastasis and explore arginine metabolism as a potential therapeutic target.
  • Analyzed incidence of bone metastasis in ARID1A-mutated TNBC patients.
  • Investigated the role of arginine metabolic pathway and its enzymes in promoting PMN-MDSC expansion in bone marrow.
  • Targeted ARG2 and ODC1 enzymes to assess their effect on reducing bone metastasis.
  • ARID1A-deficient TNBC patients show a higher incidence of bone metastasis.
  • Inhibition of ARG2 and ODC1 significantly reduces bone metastasis in ARID1A-deficient models.
  • Arginine metabolism is linked to the expansion of PMN-MDSCs in the bone marrow.

Cite This Study

Pan et al. (2026) studied this question.

synapsesocial.com/papers/6a17dbe93fad632b0f9d883dhttps://doi.org/10.1038/s41467-026-73574-3
View Full Paper
Ask AI
Bookmark
Share